ABSTRACT
Ionotropic gelation is widely used to fabricate targeting nanoparticles (NPs) with polysaccharides, leveraging their recognition by specific lectins. Despite the fabrication scheme simply involves self-assembly of differently charged components in a straightforward manner, the identification of a potent combinatory formulation is usually limited by structural diversity in compound collections and trivial screen process, imposing crucial challenges for efficient formulation design and optimization. Herein, we report a diversity-oriented combinatory formulation screen scheme to identify potent gene delivery cargo in the context of precision cardiac therapy. Distinct categories of cationic compounds are tested to construct RNA delivery system with an ionic polysaccharide framework, utilizing a high-throughput microfluidics workstation coupled with streamlined NPs characterization system in an automatic, step-wise manner. Sequential computational aided interpretation provides insights in formulation optimization in a broader scenario, highlighting the usefulness of compound library diversity. As a result, the out-of-bag NPs, termed as GluCARDIA NPs, are utilized for loading therapeutic RNA to ameliorate cardiac reperfusion damages and promote the long-term prognosis. Overall, this work presents a generalizable formulation design strategy for polysaccharides, offering design principles for combinatory formulation screen and insights for efficient formulation identification and optimization.
Subject(s)
Nanoparticles , Polysaccharides , Polysaccharides/chemistry , Nanoparticles/chemistry , Animals , Humans , Mice , Gene Transfer Techniques , RNAi Therapeutics/methods , RNA Interference , Male , RNA, Small Interfering/administration & dosage , RNA, Small Interfering/chemistry , Mice, Inbred C57BL , Myocardial Reperfusion Injury/therapyABSTRACT
This study aimed to develop a pan-genotypic and multifunctional small interfering RNA (siRNA) against hepatitis B virus (HBV) with an efficient delivery system for treating chronic hepatitis B (CHB), and explore combined RNA interference (RNAi) and immune modulatory modalities for better viral control. Twenty synthetic siRNAs targeting consensus motifs distributed across the whole HBV genome were designed and evaluated. The lipid nanoparticle (LNP) formulation was optimized by adopting HO-PEG2000-DMG lipid and modifying the molar ratio of traditional polyethylene glycol (PEG) lipid in LNP prescriptions. The efficacy and safety of this formulation in delivering siHBV (tLNP/siHBV) along with the mouse IL-2 (mIL-2) mRNA (tLNP/siHBVIL2) were evaluated in the rAAV-HBV1.3 mouse model. A siRNA combination (terms "siHBV") with a genotypic coverage of 98.55% was selected, chemically modified, and encapsulated within an optimized LNP (tLNP) of high efficacy and security to fabricate a therapeutic formulation for CHB. The results revealed that tLNP/siHBV significantly reduced the expression of viral antigens and DNA (up to 3log10 reduction; vs PBS) in dose- and time-dependent manners at single-dose or multi-dose frequencies, with satisfactory safety profiles. Further studies showed that tLNP/siHBVIL2 enables additive antigenic and immune control of the virus, via introducing potent HBsAg clearance through RNAi and triggering strong HBV-specific CD4+ and CD8+ T cell responses by expressed mIL-2 protein. By adopting tLNP as nucleic acid nanocarriers, the co-delivery of siHBV and mIL-2 mRNA enables synergistic antigenic and immune control of HBV, thus offering a promising translational therapeutic strategy for treating CHB.
Subject(s)
Hepatitis B virus , Interleukin-2 , Nanoparticles , RNA, Small Interfering , Animals , Mice , Hepatitis B virus/genetics , Interleukin-2/genetics , Interleukin-2/immunology , Interleukin-2/pharmacology , Humans , RNA, Small Interfering/genetics , RNA, Small Interfering/administration & dosage , Nanoparticles/chemistry , RNA, Messenger/genetics , Hepatitis B, Chronic/therapy , Hepatitis B, Chronic/genetics , Hepatitis B, Chronic/virology , RNA Interference , Hepatitis B/therapy , Hepatitis B/genetics , Hepatitis B/virology , RNAi Therapeutics , LiposomesABSTRACT
The clinical use of RNA interference (RNAi) molecular mechanisms has introduced a novel, growing class of RNA therapeutics capable of treating diseases by controlling target gene expression at the posttranscriptional level. With the newly approved nedosiran (Rivfloza), there are now six RNAi-based therapeutics approved by the United States Food and Drug Administration (FDA). Interestingly, five of the six FDA-approved small interfering RNA (siRNA) therapeutics [patisiran (Onpattro), lumasiran (Oxlumo), inclisiran (Leqvio), vutrisiran (Amvuttra), and nedosiran] were revealed to act on the 3'-untranslated regions of target mRNAs, instead of coding sequences, thereby following the common mechanistic action of genome-derived microRNAs (miRNA). Furthermore, three of the FDA-approved siRNA therapeutics [patisiran, givosiran (Givlaari), and nedosiran] induce target mRNA degradation or cleavage via near-complete rather than complete base-pair complementarity. These features along with previous findings confound the currently held characteristics to distinguish siRNAs and miRNAs or biosimilars, of which all converge in the RNAi regulatory pathway action. Herein, we discuss the RNAi mechanism of action and current criteria for distinguishing between miRNAs and siRNAs while summarizing the common and unique chemistry and molecular pharmacology of the six FDA-approved siRNA therapeutics. The term "RNAi" therapeutics, as used previously, provides a coherently unified nomenclature for broader RNAi forms as well as the growing number of therapeutic siRNAs and miRNAs or biosimilars that best aligns with current pharmacological nomenclature by mechanism of action. SIGNIFICANCE STATEMENT: The common and unique chemistry and molecular pharmacology of six FDA-approved siRNA therapeutics are summarized, in which nedosiran is newly approved. We point out rather a surprisingly mechanistic action as miRNAs for five siRNA therapeutics and discuss the differences and similarities between siRNAs and miRNAs that supports using a general and unified term "RNAi" therapeutics to align with current drug nomenclature criteria in pharmacology based on mechanism of action and embraces broader forms and growing number of novel RNAi therapeutics.
Subject(s)
RNA, Small Interfering , Humans , RNA, Small Interfering/genetics , RNAi Therapeutics/methods , RNA Interference , Animals , MicroRNAs/geneticsABSTRACT
The treatment of hepatocellular carcinoma (HCC) remains a major challenge in the medical field. Lenvatinib, a multi-target tyrosine kinase inhibitor, has demonstrated anti-HCC effects by targeting and inhibiting pathways such as vascular endothelial growth factor receptor 1-3 (VEGFR1-3). However, the therapeutic efficacy of Lenvatinib is subject to various influences, with the hypoxic microenvironment of the tumor being a pivotal factor. Consequently, altering the hypoxic milieu of the tumor emerges as a viable strategy to augment the efficacy of Lenvatinib. Hypoxia-inducible factor-1α (HIF-1α), synthesized by tumor cells in response to oxygen-deprived conditions, regulates the expression of resistance genes, promotes tumor angiogenesis and cell proliferation, enhances tumor cell invasion, and confers resistance to radiotherapy and chemotherapy. Thus, we constructed a self-designed siRNA targeting HIF-1α to suppress its expression and improve the efficacy of Lenvatinib in treating HCC. The therapeutic efficacy of siRNA-HIF-1α in combination with Lenvatinib on HCC were evaluated through in vivo and in vitro experiments. The results showed that the recombinant Salmonella delivering siRNA-HIF-1α in combination with Lenvatinib effectively inhibited tumor growth and prolonged the survival of tumor-bearing mice. This treatment approach reduced cell proliferation and angiogenesis in HCC tissues while promoting tumor cell apoptosis. Additionally, this combined therapy significantly increased the infiltration of T lymphocytes and M1 macrophages within the tumor microenvironment, as well as elevated the proportion of immune cells in the spleen, thereby potentiating the host's immune response against the tumor.
Subject(s)
Carcinoma, Hepatocellular , Hypoxia-Inducible Factor 1, alpha Subunit , Liver Neoplasms , Phenylurea Compounds , Quinolines , RNA, Small Interfering , RNAi Therapeutics , Salmonella , Animals , Mice , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/therapy , Cell Line, Tumor , Hypoxia-Inducible Factor 1, alpha Subunit/antagonists & inhibitors , Hypoxia-Inducible Factor 1, alpha Subunit/genetics , Liver Neoplasms/drug therapy , Liver Neoplasms/therapy , Phenylurea Compounds/therapeutic use , Quinolines/therapeutic use , RNA, Small Interfering/administration & dosage , RNA, Small Interfering/therapeutic use , Tumor Microenvironment , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism , Combined Modality Therapy , RNAi Therapeutics/methodsABSTRACT
PURPOSE OF REVIEW: RNA interference (RNAi)-based therapies that target specific gene products have impacted clinical medicine with 16 FDA approved drugs. RNAi therapy focused on reducing plasma lipoprotein(a) [Lp(a)] levels are under evaluation. RECENT FINDINGS: RNAi-based therapies have made significant progress over the past 2 decades and currently consist of antisense oligonucleotides (ASO) and small interfering RNA (siRNA). Chemical modification of the RNA backbone and conjugation of siRNA enables efficient gene silencing in hepatocytes allowing development of effective cholesterol lowering therapies. Multiple lines of evidence suggest a causative role for Lp(a) in atherosclerotic cardiovascular disease, and recent analyses indicate that Lp(a) is more atherogenic than low density lipoprotein- cholesterol (LDL-C). These findings have led to the 'Lp(a) hypothesis' that lowering Lp(a) may significantly improve cardiovascular outcomes. Four RNAi-based drugs have completed early phase clinical trials demonstrating >80% reduction in plasma Lp(a) levels. Phase 3 clinical trials examining clinical outcomes with these agents are currently underway. SUMMARY: Currently, four RNAi-based drugs have been shown to be effective in significantly lowering plasma Lp(a) levels. Clinical outcome data from phase 3 trials will evaluate the Lp(a) hypothesis.
Subject(s)
Lipoprotein(a) , RNA Interference , RNA, Small Interfering , Humans , Lipoprotein(a)/blood , RNA, Small Interfering/therapeutic use , Oligonucleotides, Antisense/therapeutic use , Atherosclerosis/therapy , Atherosclerosis/drug therapy , RNAi Therapeutics/methodsABSTRACT
BACKGROUND: Lumasiran is the first RNA interference (RNAi) therapy of primary hyperoxaluria type 1 (PH1). Here, we report on the rapid improvement and even disappearance of nephrocalcinosis after early lumasiran therapy. CASE-DIAGNOSIS/TREATMENT: In patient 1, PH1 was suspected due to incidental discovery of nephrocalcinosis stage 3 in a 4-month-old boy. Bilateral nephrocalcinosis stage 3 was diagnosed in patient 2 at 22 months concomitantly to acute pyelonephritis. Urinary oxalate (UOx) and glycolate (UGly) were increased in both patients allowing to start lumasiran therapy before genetic confirmation. Nephrocalcinosis started to improve and disappeared after 27 months and 1 year of treatment in patients 1 and 2, respectively. CONCLUSION: These cases illustrate the efficacy of early lumasiran therapy in infants to improve and even normalize nephrocalcinosis. As proposed in the 2023 European guidelines, the interest of starting treatment quickly without waiting for genetic confirmation may have an impact on long-term outcomes.
Subject(s)
Hyperoxaluria, Primary , Nephrocalcinosis , Humans , Nephrocalcinosis/genetics , Nephrocalcinosis/diagnosis , Nephrocalcinosis/therapy , Male , Infant , Hyperoxaluria, Primary/genetics , Hyperoxaluria, Primary/diagnosis , Hyperoxaluria, Primary/therapy , Hyperoxaluria, Primary/urine , Hyperoxaluria, Primary/complications , RNAi Therapeutics/methods , Treatment Outcome , Glycolates/therapeutic use , Glycolates/urineABSTRACT
Ki67 is a well-known proliferation marker for the evaluation of cell proliferation. Numerous studies have indicated that Ki67 index independently predicts cancer progression. Moreover, because Ki67 is highly expressed in malignant cells but almost could not be detected in normal cells, it has become a promising target for cancer therapy. In this review, we summarize recent advances in Ki67 targeted cancer therapy. In particular, we highlight recent development on the exploitation of Ki67 promoter to drive the expression of siRNAs or therapeutic genes in cancer cells specifically. The use of Ki67 as an attractive target opens a new avenue for cancer therapy
No disponible
Subject(s)
Humans , Kidney Neoplasms/diagnosis , Kidney Neoplasms/therapy , Genetic Therapy , Cell Proliferation/genetics , Prognosis , Radiotherapy , Kidney Neoplasms/genetics , RNAi TherapeuticsABSTRACT
A anemia falciforme é a doença monogênica de maior ocorrência mundial e é causada pela presença de hemoglobina S (HbS), uma variante estrutural decorrente da substituição de um aminoácido na cadeia ß globina. Essa mutação altera as propriedades bioquímicas e fisiológicas da hemoglobina, que tem a tendência de formar agregados fibrilares, no estado desoxigenado, o que produz alterações morfológicas (falcização) e funcionais da hemácia. Assim, todas as manifestações clínicas observadas na doença decorrem da presença da HbS e têm início com a hemólise e a vaso-oclusão, desencadeando os demais eventos da doença, que podem afetar os órgãos e sistemas orgânicos. O tratamento baseia-se no controle dos sintomas. O único medicamento aprovado que altera o curso da doença é o antineoplásico hidroxiureia e, apesar de seu sucesso clínico, não é curativo e pode desencadear muitos efeitos adversos. O único tratamento curativo é o transplante de células tronco hematopoéticas. A terapia gênica vem sendo estudada há mais de 30 anos e alguns estudos clínicos estão sendo realizados. Novas abordagens moleculares como a edição do genoma, uso de RNA terapêutico e manipulação genética para indução da síntese de hemoglobina fetal emergem como possibilidades para a cura da doença. (AU)
Sickle cell anemia is the most common monogenic disease worldwide and it is caused by the presence of sickle hemoglobin (HbS), structural variant hemoglobin with one amino acid substitution in the ß globin chain. This mutation changes the biochemical and physiological properties of hemoglobin, which has the tendency, in the de-oxygenated state, to form fibrous aggregates, which produces morphological (sickling) and functional changes in red blood cells. Thus, all the observed disease clinical manifestations arise from the presence of HbS and begin with hemolysis of the red blood cell and vaso-occlusion, triggering other disease events, which can affect the body organs and systems as a whole. Nowadays, treatment is based mainly in symptoms control. The only drug approved that changes the course of the disease is the antineoplastic Hydroxyurea and, despite its clinical success, it is not curative and can trigger many adverse effects. The only curative treatment is the hematopoietic stem cells transplantation. Gene therapy has been studied for more than 30 years and some clinical studies are being in course. New molecular approaches as the genome editing, therapeutic RNA and genetic manipulation to stimulate fetal hemoglobin synthesis emerge as possible curative options for the disease. (AU)
Subject(s)
Therapeutics , Anemia, Sickle Cell , Hemoglobin, Sickle , Genetic Therapy , Molecular Targeted Therapy , RNAi Therapeutics , HydroxyureaABSTRACT
El neuroblastoma (NB) es el tumor sólido más común en niños y adolescentes y representa hasta un 15% de la muerte infantil asociada al cáncer. Tiene su origen en el sistema nervioso simpático y su comportamiento puede llegar a ser muy agresivo y no responder a los tratamientos actuales. En esta revisión se recogen nuevas alternativas terapéuticas basadas en la epigenética, es decir, en moduladores de la expresión génica como los microRNAs y su potencial aplicación clínica en NB
Neuroblastoma (NB) is the most common solid tumour in children and adolescents, and accounts for up to 15% of all cancer deaths in this group. It originates in the sympathetic nervous system, and its behaviour can be very aggressive and become resistant to current treatments. A review is presented, summarising the new alternative therapies based on epigenetics, i.e., modulators of gene expression, such as microRNAs and their potential application in the clinical practice of NB treatment
Subject(s)
Humans , Male , Female , Child , Adolescent , Neuroblastoma/genetics , Neuroblastoma , Neuroblastoma/drug therapy , RNAi Therapeutics/instrumentation , RNAi Therapeutics , Tumor Suppressor Protein p53/analysis , MicroRNAs/analysis , MicroRNAs/therapeutic use , Epigenetic Repression/radiation effects , Response Evaluation Criteria in Solid Tumors , Sympathetic Nervous System/pathology , Sympathetic Nervous System , Immune System , Immune System/pathology , RNA Polymerase II/therapeutic use , RNA Polymerase III/therapeutic use , RNAi Therapeutics/methods , RNAi Therapeutics/standardsABSTRACT
Background: The forkhead box M1 (FOXM1), an important regulator of cell differentiation and proliferation, is overexpressed in a number of aggressive human carcinomas. However, the clinical significance of FOXM1 signaling in human colorectal cancer (CRC) pathogenesis remains unknown. The aim of this study was to evaluate the role of FOXM1 in CRC tumorigenesis. Methods: We investigated FOXM1 expression in 103 cases of primary CRC and matched normal tissue specimens and explored the underlying mechanisms of altered FOXM1 expression and the impact of this altered expression on CRC proliferation and metastasis using in vitro models of CRC. Results: The results showed that high expression of FOXM1 staining was 85.44 % (88/103) in 103 cases of CRC and 20.39 % (21/103) in 103 cases of adjacent noncancerous tissue samples; the difference of FOXM1 expression between two groups was statistically significant (P < 0.001). Silencing of FOXM1 inhibited the proliferation of CRC cells, and the invasion and migration of CRC cells were distinctly suppressed. Furthermore, FOXM1 knockdown led to substantial reductions in VEGF-A levels in CRC cell lines. Conclusions: Our data suggest that the pathogenesis of CRC maybe mediated by FOXM1, and FOXM1 could represent selective targets for the molecularly targeted treatments of CRC
No disponible
Subject(s)
Humans , Male , Female , Oncogene Proteins v-fos , Oncogene Proteins v-fos/isolation & purification , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/therapy , RNA Interference , RNA Interference/radiation effects , RNAi Therapeutics/methods , Cell Proliferation , Cell Proliferation/radiation effectsABSTRACT
La descripción del mecanismo de interferencia mediada por ARN (ARNi) ha despertado un enorme interés en todos los campos de la biomedicina. Una vía previamente desconocida en la que fragmentos de doble hebra de ARN de 21 a 23 residuos (ARNpi) median la degradación específica de secuencias de ARNm se está convirtiendo en una de las herramientas más poderosas en la investigación en biología celular y genética. Existen grandes expectativas en el uso terapéutico silenciamiento genético por medio de ARNi que se basan en su potencia, especificidad y fisiología. La comunicación de las primeras evidencias sobre la efectividad del ARNi como supresor de la replicación de VIH ha estimulado de nuevo el desarrollo de estrategias de terapia génica o molecular para el tratamiento de la infección por VIH
The description of the mechanism of RNA interference (RNAi) has generated enormous interest in the biomedical field. A previously unrecognized pathway in which small interfering, 21 to 23 mer, double-stranded RNA (siRNA) mediates sequence-specific degradation of mRNA is becoming one the most useful techniques in cell biology and genetics research. Based on the potency, specificity and physiology of RNAi to silence gene expression, much is expected from its use as a therapeutic tool. The first evidence of RNAi as a suppressor of HIV replication has already been reported, thus providing a new impetus to the development of molecular or gene therapy approaches to HIV infection